


# Report on the data collection and selection on TB disease and candidate vaccines/treatments.

---

31/07/2018

The present document contains the report of Deliverable 1 WP2.

Author: Barry Walker 	replaces version	n.a.	from	n.a.	Page
	valid from date (dd/mm/yyyy)		31/07/2018		1 / 2
	Recipient		STriTuVaD Consortium		

## Topic

Partner: TBVI: Deliverable 1 WP2: Summaries, Reports and Information relating to Data collection and selection on TB disease and candidate vaccines/treatments.

## Discussion

Partner: TBVI, UNICT.

Over the course of the project to date, TBVI have provided through response mode actions, copies of targeted reports, summaries and publications as requested. Information on the immunology of TB disease, vaccine responses, granuloma formation and cytokine pathways has been provided to UNICT partner with the aim to satisfy required data for the implementation of the simulation framework. Additional links have been made between the STriTuVaD consortium and a range of databases of clinical trial information, along with links to other relevant EC consortium (eg: EMI-TB) who have recent experience and clinical data on clinical trials of TB vaccines.

Below are a few of the links and information/reports that have been shared with the STriTuVaD team:

- Summary report of Literature accessible via PubMed relating to Clinical Trials of TB vaccines.
- <https://www.fda.gov/Drugs/NewsEvents/ucm604837.htm>.
- <http://www.immport.org/import-open/public/home/home>.
- N Engl J Med 2018;379:138-49.
- Clinical and Developmental Immunology: Volume 2012, Article ID 139127, 14 pages.
- Frontiers in Immunology April 2013; Vol 4; Article 98.
- Made links and provided contact details for Rajko Reljic coordinator of EMI-TB for further discussions.
- Discussed STriTuVaD with mathematical modellers at LSHTM (London) and provided contact details to STriTuVaD for further discussions.

## Conclusion

Partner TBVI: The deliverable for WP2 as required by TBVI has provided the data needed for the first stage generation of the immune engine as required by the Scope of Work. As the process continues and data refinement/expansion may be required we will be active in providing such information as is available and relevant to the development programme, in agreement with TBVI and the STriTuVaD consortium.